drugset / Trial / NCT05061992

A Trial to Improve Quality of Life in People With Cirrhosis

NCT05061992

Phase 2/3 Completed 56 enrolled University of Michigan
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is being completed to evaluate whether a crystallized form of lactulose (Kristalose) will improve quality of life, sleep and cognitive function in patients with cirrhosis that have not been diagnosed with Hepatic Encephalopathy (HE), but report reduced quality of life.

Timeline

Start
2021-11-10
Primary completion
2022-11-01
Completion
2022-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lactulose Other / unclassified 20 g

Indications